19th-banner-rev.gif

Albany 2013: Book of Abstracts

category image Albany 2013
Conversation 18
June 11-15 2013
©Adenine Press (2012)

Structure based engineering to generate high affinity immunotherapy for the drug of abuse

Methamphetamine (METH) abuse is a major threat in the US and worldwide without any FDA approved medications. Anti-METH antibody antagonists block or slow the rate of METH entry into the brain and have shown efficacy in preclinical studies (Peterson et al. 2008). A key determinant of the antibody’s efficacy is its affinity for METH and we attempted to enhance the efficacy by designing mutations to alter the shape or the electrostatic character of the binding pocket. Towards this goal, we developed a single chain anti-METH antibody fragment (scFv6H4) from a parent IgG (Peterson et al. 2008). The crystal structure of scFv-6H4 in complex with METH was determined (celikel et al., 2009). Based on its elucidated binding interactions, we designed point mutations in the binding pocket to improve its affinity for METH and amphetamine (AMP), the active metabolite of METH. The mutants; scFv-S93T,-I37M and –Y34M were cloned, expressed in yeast and tested for affinity against METH and AMP. Two mutants showed enhanced binding affinity for METH; scFv-I37M by 1.3 fold and scFv-S93T by 2.6 fold. Additionally, all the mutants showed increase in affinity for AMP; scFv-I37M by 56 fold, scFv-S93T by 17 fold and scFvY34M by 5 fold. Crystal structure for one of the high affinity mutant scFv-S93T in complex with METH was determined (Figure, top). Binding pocket of the mutant is more hydrophobic in comparison with the wild type. ScFv-6H4 binds METH in a deep pocket containing two water molecules. The substitution of a serine residue by a threonine leads to the expulsion of a water molecule (Figure, bottom), relieving some unfavorable contacts between hydrocarbon atoms of METH and the water molecule and increasing the affinity to sub-nanomolar range. Therefore, the present study shows that efficacy could be enhanced by altering the hydrophobicity or the shape of the binding pocket.

thakkar.gif

References

    Peterson EC, Laurenzana EM, Atchley WT, Hendrickson HP, Owens SM (2008). Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamine. J. Pharmacol. Exp. Ther. 08, 124-33.

    Celikel R, Peterson EC, Owens SM, Varughese KI (2009). Crystal structures of a therapeutic single chain antibody in complex with two drugs of abuse-Methamphetamine and 3,4-methylenedioxymethamphetamine, Protein Sci. 09, 2336-45.


Shraddha Thakkar
Nisha Nanaware-Kharade
Guillermo Gonzalez III
Reha Celikel
Eric Peterson
Kottayil I. Varughese

University of Arkansas for Medical Sciences
Little Rock, AR 72205

Phone: 501-686-7160
kivarughese@uams.edu